



DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

**Joint Meeting of the
National Center for Advancing Translational Sciences Advisory Council
(8th Meeting) and Cures Acceleration Network Review Board (10th
Meeting)**

January 15, 2015

8:30 a.m. - 5:00 p.m.

Building 31C, 6th Floor, Conference Room 6
Bethesda, Maryland 20892

Future Advisory Council & CAN Review Board Joint Meetings

2015

June 17-18
September 3-4

2016

January 14-15
May 12-13
September 15-16

Future CAN Review Board (only) Meetings (by phone)

2015

December 11

2016

December 8

Agenda – OPEN SESSION

Open Session of the meeting will be webcast. To view, please go to: <http://videocast.nih.gov/summary.asp?live=15419>

8:30 - 8:50 a.m.

Call to Order, Open Session

Christopher P. Austin, M.D., Director, NCATS; Chairperson - Advisory Council

Freda C. Lewis-Hall, M.D., Chief Medical Officer, Pfizer; Chairperson - CAN Review Board

8:50 - 9:00 a.m.

Approval of Minutes from September 2014 Joint Meeting

Confirmation of Dates for Future NCATS Advisory Council/CAN Review Board Meetings

Danilo A. Tagle, Ph.D., M.S., Executive Secretary, NCATS Advisory Council

Introduction of New Staff

9:00 - 10:00 a.m.	<p>NCATS Director's Report Christopher P. Austin, M.D., Director, NCATS</p> <p>Discussion</p>
10:00 - 10:30 a.m.	<p>BREAK</p>
10:30 - 11:30 a.m.	<p>Overview of Rare Diseases Clinical Research Network Pamela M. McInnes, D.D.S., M.Sc.(Dent.), Deputy Director, and Acting Director of Office of Rare Diseases Research, NCATS</p> <p>The Transformation of Clinical Research in Vasculitis Through the Rare Diseases Clinical Research Network Peter A. Merkel, M.D., M.P.H., Professor of Medicine and Epidemiology, Chief of Rheumatology, University of Pennsylvania</p> <p>Perspective from an RDCRN Consortium's PAG as Research Partner Michele Manion, B.S., Vice President, Executive Director, Founder, Primary Ciliary Dyskinesia Foundation</p> <p>Discussion</p>
11:30 a.m. - Noon	<p>Report from Council Subcommittee</p> <p>Medical Technologies (Devices and Diagnostics) Frank L. Douglas, Ph.D., M.D., President and CEO, Austen Bioinnovation Institute in Akron</p> <p>Discussion</p>
Noon - 1:00 p.m.	<p>LUNCH</p>
1:00 - 2:00 p.m.	<p>CTSA Update Petra Kaufmann, M.D., M.Sc., Director, Division of Clinical Innovation, NCATS</p> <p>Discussion</p>
2:00 - 3:00 p.m.	<p>Council and CAN RB-Initiated Discussion Advisory Council and CAN Review Board Members</p> <p>Discussion</p>
3:00 p.m.	<p>Adjourn, Open Session</p>

3:15 - 5:00 p.m.

Closed Session

This portion of the meeting is closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S. Code and Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2).

Review of Conflict of Interest, Confidentiality and Council Procedures

Danilo A. Tagle, Ph.D., M.S., Executive Secretary, NCATS Advisory Council and CAN Review Board

Council Consideration of Pending Applications

Danilo A. Tagle, Ph.D., M.S., Executive Secretary, NCATS Advisory Council and CAN Review Board